Brought to you by 
Ranbaxy gets US rights to Cipher's CIP-Isotretinoin; deal later amended
15 Nov 2021
Executive Summary
Ranbaxy Pharmaceuticals has licensed exclusive US development and distribution rights to Cipher Pharmaceuticals' (drug delivery technologies) CIP-Isotretinoin (isotretinoin) for severe nodular acne.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- Manufacturing or Supply
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ranbaxy gets US rights to Cipher's CIP-Isotretinoin; deal later amended
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice